These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 24051302)

  • 41. Thrombin generation in patients with factor XI deficiency and clinical bleeding risk.
    Rugeri L; Quélin F; Chatard B; De Mazancourt P; Negrier C; Dargaud Y
    Haemophilia; 2010 Sep; 16(5):771-7. PubMed ID: 20398070
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Biochemical and immunological properties of four intravenous Immunoglobulin G preparations.
    Redwan EL
    Hum Antibodies; 2002; 11(3):79-84. PubMed ID: 12454368
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Factor XIIa-inhibited diluted thromboplastin time can reflect coagulation process].
    He S; Xiong S; He R; He X; Liu F; Han J; Li J
    Zhonghua Xue Ye Xue Za Zhi; 2000 Mar; 21(3):118-21. PubMed ID: 11876967
    [TBL] [Abstract][Full Text] [Related]  

  • 44. HPLC fingerprinting approach for raw material assessment and unit operation tracking for IVIG production from Cohn I+II+III fraction.
    Peljhan S; Jakop T; Šček D; Skvarča V; Goričar B; Žabar R; Mencin N
    Electrophoresis; 2017 Nov; 38(22-23):2880-2885. PubMed ID: 28727158
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Factors associated with the presence of circulating active tissue factor and activated factor XI in stable angina patients.
    Ząbczyk M; Butenas S; Plicner D; Fijorek K; Sadowski J; Undas A
    Blood Coagul Fibrinolysis; 2012 Apr; 23(3):189-94. PubMed ID: 22343680
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The role of factor XI in a dilute thromboplastin assay of extrinsic coagulation pathway.
    He R; Xiong S; He X; Liu F; Han J; Li J; He S
    Thromb Haemost; 2001 Jun; 85(6):1055-9. PubMed ID: 11434684
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intravenous immunoglobulin products contain specific antibodies to recombinant human tau protein.
    Smith LM; Coffey MP; Klaver AC; Loeffler DA
    Int Immunopharmacol; 2013 Aug; 16(4):424-8. PubMed ID: 23669333
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vitro effects of detergent sclerosants on coagulation, platelets and microparticles.
    Parsi K; Exner T; Connor DE; Ma DD; Joseph JE
    Eur J Vasc Endovasc Surg; 2007 Dec; 34(6):731-40. PubMed ID: 17919946
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Evaluation of antibacterial and antitoxic activity of normal human immunoglobulin for intravenous use (IVIG)].
    Bucholc B; Banach W; Wysokińska T; Cieślik A; Chodorowska M
    Med Dosw Mikrobiol; 1996; 48(1-2):87-94. PubMed ID: 8926773
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Characterization of proteases in AHF concentrates: effect on factor VIII:von Willebrand protein as assessed by high-pressure gel permeation chromatography.
    Orthner CL
    J Lab Clin Med; 1984 Nov; 104(5):816-28. PubMed ID: 6436416
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Factor XIa dimer in the activation of factor IX.
    Sinha D; Marcinkiewicz M; Lear JD; Walsh PN
    Biochemistry; 2005 Aug; 44(30):10416-22. PubMed ID: 16042419
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of aprotinin on plasma coagulation kinetics determined by thrombelastography: role of Factor XI.
    Nielsen VG
    Acta Anaesthesiol Scand; 2006 Feb; 50(2):168-72. PubMed ID: 16430537
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Viral safety of Nanogam, a new 15 nm-filtered liquid immunoglobulin product.
    Terpstra FG; Parkkinen J; Tölö H; Koenderman AH; Ter Hart HG; von Bonsdorff L; Törmä E; van Engelenburg FA
    Vox Sang; 2006 Jan; 90(1):21-32. PubMed ID: 16359352
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Investigations of prion and virus safety of a new liquid IVIG product.
    Stucki M; Boschetti N; Schäfer W; Hostettler T; Käsermann F; Nowak T; Gröner A; Kempf C
    Biologicals; 2008 Jul; 36(4):239-47. PubMed ID: 18337119
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Process steps for the fractionation of immunoglobulin (Ig) G depleted of IgA, isoagglutinins, and devoid of in vitro thrombogenicity.
    Cheng JH; Wu YW; Wang CY; Wu SS; Hong CL; Chan KW; Liao LX; Cao X; Wang B; Burnouf T
    Blood Transfus; 2021 Nov; 19(6):467-478. PubMed ID: 34369872
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Characterization and viral safety validation study of a pasteurized therapeutic concentrate of antithrombin III obtained through affinity chromatography.
    Biescas H; Gensana M; Fernández J; Ristol P; Massot M; Watson E; Vericat F
    Haematologica; 1998 Apr; 83(4):305-11. PubMed ID: 9592979
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Manufacturing process optimization of ADMA Biologics' intravenous immunoglobulin products, BIVIGAM
    Wasserman RL; Garcia D; Greener BN; Kestenberg K; Pinkert A; Mond J; Grossman A
    Immunotherapy; 2019 Nov; 11(16):1423-1433. PubMed ID: 31596642
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Platelets significantly modify procoagulant activities in haemophilia A.
    Wartiovaara-Kautto U; Joutsi-Korhonen L; Ilveskero S; Armstrong E; Lassila R
    Haemophilia; 2011 Sep; 17(5):743-51. PubMed ID: 21682825
    [TBL] [Abstract][Full Text] [Related]  

  • 59. One IVIG mystery solved, another demands vigilance.
    Thompson CA
    Am J Health Syst Pharm; 2012 Feb; 69(4):271-2. PubMed ID: 22302248
    [No Abstract]   [Full Text] [Related]  

  • 60. Hyperimmune globulins and same-day thrombotic adverse events as recorded in a large healthcare database during 2008-2011.
    Menis M; Sridhar G; Selvam N; Ovanesov MV; Divan HA; Liang Y; Scott D; Golding B; Forshee R; Ball R; Anderson SA; Izurieta HS
    Am J Hematol; 2013 Dec; 88(12):1035-40. PubMed ID: 23907744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.